Improvement in immune dysfunction after FOLFOX chemotherapy for stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome
Keyword(s):
2021 ◽
Vol 22
(8)
◽
pp. 2391-2397
2015 ◽
Vol 14
(4)
◽
pp. 262-268.e1
◽
Keyword(s):